Active Recombinant Human CTSK Protein

• Cat.No.: CTSK-9392H
• Product Overview: Recombinant Human CTSK Protein (115-329 aa) was expressed in E. coli.

Specification

• Description: Cathepsin K, a member of the papain cysteine proteinase family is the predominant proteinase responsible for the resorption of the bone matrix. Cathepsin cleaves proteins such as collagen type I, collagen type II and osteonectin, thereby playing a role in bone remodeling and resorption in osteoporosis, osteolytic bone metastasis and rheumatoid arthritis.
• Source: E. coli
• Species: Human
• Form: 0.5 mg/ml solution in 25 mM Na2HPO4 and 500 mM NaCl (pH 7.0) with 50% glycerol.
• Bio-activity: The specific activity is >5000 mU/mg (1U = 1 µmole/min/mg) as measured by Cathepsin K Activity Assay Kit
• Molecular Mass: 23.5 kDa
• Purity: ≥90%
• Storage: Store at -80 centigrade. Centrifuge the vial prior to opening.
• Tag: Non
• Protein length: 115-329

Gene Information

• Gene Name: CTSK cathepsin K [ Homo sapiens ]
• Official Symbol: CTSK
• Synonyms: CTSK; cathepsin K; cathepsin K (pycnodysostosis) , CTSO, CTSO2, PYCD; PKND; cathepsin O; cathepsin X; cathepsin O1; cathepsin O2; CTSO; PYCD; CTS02; CTSO1; CTSO2; MGC23107
• Gene ID: 1513
• mRNA Refseq: NM_000396
• Protein Refseq: NP_000387
• MIM: 601105
• UniProt ID: P43235

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.